Core Insights - WuXi Biologics has been recognized for its commitment to sustainability and transparency by receiving the Outstanding ESG Disclosure award at the Hong Kong ESG Reporting Awards (HERA) 2025, marking a significant achievement in its ESG journey [1][2] - The company emphasizes that transparent ESG reporting serves as a strategic advantage, enhancing trust and confidence among stakeholders, including clients, investors, and regulators [2][3] ESG Commitment - WuXi Biologics has a history of receiving accolades for its ESG efforts, including the ESG Report Benchmark Award from HERA in the previous year, which underscores the consistency of its progressive ESG initiatives [2] - The company actively participates in global sustainability initiatives, such as the United Nations Global Compact (UNGC) and the Pharmaceutical Supply Chain Initiative (PSCI), and has received numerous recognitions, including an MSCI AAA Rating and a Platinum Medal from EcoVadis [4] Business Operations - As of June 30, 2025, WuXi Biologics supports 864 integrated client projects, with 24 of these in commercial manufacturing, showcasing its extensive operational capabilities [6] - The company employs over 12,000 skilled professionals across multiple countries, including China, the United States, Ireland, Germany, and Singapore, leveraging its expertise to provide efficient and cost-effective biologics solutions [6] Sustainability Focus - WuXi Biologics views sustainability as essential for long-term business growth and is committed to driving green technology innovations to offer advanced Green CRDMO solutions [7] - The company aims to create shared value by collaborating with stakeholders to foster positive social and environmental impacts, promoting responsible practices throughout the value chain [7]

Core Insights - WuXi Biologics has been included in the 2025 Hang Seng Corporate Sustainability Benchmark Index, being the only pharmaceutical company recognized in this index [1][10] - The company has also been previously honored with inclusion in the HSI ESG Index and the Hang Seng ESG 50 Index, highlighting its strong ESG performance [1][10] Sustainability Recognition - The Hang Seng Corporate Sustainability Benchmark Index acknowledges publicly listed companies with outstanding ESG performance, based on an annual sustainability assessment by the Hong Kong Quality Assurance Agency (HKQAA) [2] - WuXi Biologics has received multiple accolades for its sustainability efforts, including MSCI AAA ESG Rating, EcoVadis Platinum Medal, and recognition in the Dow Jones Sustainability Indices [5] Commitment to Sustainability - WuXi Biologics integrates sustainability principles into its business model, focusing on energy and resource efficiency, governance transparency, and employee welfare [3][8] - The company is aligned with the United Nations Sustainable Development Goals and has set greenhouse gas emissions-reduction targets approved by the Science Based Targets initiative (SBTi) [4] Business Operations - WuXi Biologics operates as a global provider of biologics Green CRDMO solutions, supporting 864 integrated client projects, including 24 in commercial manufacturing as of June 30, 2025 [7] - The company employs over 12,000 skilled professionals across various countries, leveraging technology and expertise to deliver efficient and cost-effective solutions [6][7]

Company Overview - WuXi Biologics is a leading global Contract Research, Development, and Manufacturing Organization (CRDMO) that provides end-to-end solutions for biologics from concept to commercialization [6][8] - The company employs over 12,000 skilled employees across multiple countries including China, the United States, Ireland, Germany, and Singapore [7] ESG Rating and Recognition - WuXi Biologics has achieved the highest negligible-risk tier in the Morningstar Sustainalytics ESG rating, placing it in the top 1% globally [3][9] - The company has been recognized as an Industry and Regional ESG Top-Rated Company for five consecutive years [3][9] - WuXi Biologics has received multiple accolades for its sustainability efforts, including a MSCI AAA rating, EcoVadis Platinum Medal, and inclusion in the Dow Jones Sustainability Indices [4] Commitment to Sustainability - The company emphasizes sustainability as a cornerstone of long-term business growth and is focused on driving green technology innovations [8] - WuXi Biologics collaborates with stakeholders to promote responsible practices and create positive social and environmental impacts throughout the value chain [10]

Core Viewpoint - WuXi Biologics demonstrates a strong commitment to sustainability through its 2024 Sustainability Report, highlighting significant advancements in sustainable development and corporate governance [1][3][15] Group 1: Sustainability Commitment - The company has successfully executed its "Follow and Win the Molecule" strategies while achieving notable sustainability milestones in 2024 [2] - WuXi Biologics has achieved a 30% intensity reduction in GHG emissions and a 28% reduction in water consumption compared to baseline years [7] - The Green CRDMO solution offers up to an 80% reduction in product carbon footprint, recognized by the United Nations Global Compact [9] Group 2: Governance and Stakeholder Engagement - The company has established strong corporate governance mechanisms aligned with the United Nations Sustainable Development Goals (UN SDGs) [3][4] - WuXi Biologics actively engages with stakeholders and participates in the Pharmaceutical Supply Chain Initiative (PSCI) to uphold principles in ethics, human rights, and environmental management [4] Group 3: Community and Employee Empowerment - The company supports career development for women in STEM, with 54% of STEM positions held by female employees, surpassing industry averages [5] - In 2024, nearly 10,000 employee volunteer hours were logged in local communities, emphasizing the company's commitment to social responsibility [6] Group 4: Recognition and Future Outlook - WuXi Biologics has received multiple accolades, including an MSCI AAA Rating and inclusion in the Dow Jones Sustainability Indices, reflecting its leadership in ESG [11] - Looking ahead, the company plans to continue prioritizing sustainability as a cornerstone of its innovation and operations, contributing to the UN Sustainable Development Goals [12]

Core Viewpoint - WuXi Biologics has been recognized by CDP for its leadership in climate change disclosure and performance, achieving an "A-" score for the second consecutive year, highlighting its commitment to sustainability and environmental stewardship [1][2][4]. Company Achievements - WuXi Biologics has adopted an integrated strategy to address climate change, aiming for net-zero emissions by 2050 and achieving a 30% reduction in GHG emission intensity from 2020 levels in 2024 [3]. - The company has received multiple accolades for its sustainability efforts, including an MSCI AAA Rating, EcoVadis Platinum Medal, and inclusion in the Dow Jones Sustainability Indices for two consecutive years [4]. Environmental Initiatives - WuXi Biologics is committed to the Science Based Target initiative (SBTi) and actively pursues energy-saving initiatives, including process optimization and infrastructure upgrades [3]. - The company has achieved a 100% renewable electricity supply at its Ireland site and is deploying rooftop photovoltaic power projects [3]. Industry Context - CDP serves as a global standard for corporate environmental reporting, with nearly 25,000 companies reporting their environmental data in 2024, representing two-thirds of the global market value [2]. - The recognition from CDP is significant as it influences investment and procurement decisions towards a sustainable economy [2].